<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.37" />
  <meta name="author" content="Ming Tang">

  
  
  
  
  <meta name="description" content="Senior Scientist">

  
  <link rel="alternate" hreflang="en-us" href="/publication/">

  


  

  
  
  <meta name="theme-color" content="#328cc1">
  
  
  
  
    
  
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  
  <link rel="stylesheet" href="/css/custom.css">
  

  
    <script>
      window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
      ga('create', 'UA-84019592-2', 'auto');
      
      ga('require', 'eventTracker');
      ga('require', 'outboundLinkTracker');
      ga('require', 'urlChangeTracker');
      ga('send', 'pageview');
    </script>
    <script async src="//www.google-analytics.com/analytics.js"></script>
    
    <script async src="https://cdnjs.cloudflare.com/ajax/libs/autotrack/2.4.1/autotrack.js" integrity="sha512-HUmooslVKj4m6OBu0OgzjXXr+QuFYy/k7eLI5jdeEy/F4RSgMn6XRWRGkFi5IFaFgy7uFTkegp3Z0XnJf3Jq+g==" crossorigin="anonymous"></script>
    
  

  
  <link rel="alternate" href="/publication/index.xml" type="application/rss+xml" title="DNA confesses Data speak">
  <link rel="feed" href="/publication/index.xml" type="application/rss+xml" title="DNA confesses Data speak">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@https://twitter.com/tangming2005">
  <meta property="twitter:creator" content="@https://twitter.com/tangming2005">
  
  <meta property="og:site_name" content="DNA confesses Data speak">
  <meta property="og:url" content="/publication/">
  <meta property="og:title" content="Publications | DNA confesses Data speak">
  <meta property="og:description" content="Senior Scientist">
  <meta property="og:locale" content="en-us">
  
  <meta property="og:updated_time" content="2017-01-01T00:00:00-05:00">
  

  
  

  <title>Publications | DNA confesses Data speak</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">DNA confesses Data speak</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-right">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#projects">
            
            <span>Projects</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#talks">
            
            <span>Talks &amp; Teachings</span>
            
          </a>
        </li>

        
        

        
        
        
        
        

        <li class="nav-item">
          <a href="/#cv">
            
            <span>CV</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>





<div class="container">
  <div class="row">
    <div class="col-md-12">
      <h1>Publications</h1>

      

      
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      
        
        
      

      <p>
        Filter by type:

        <select class="pub-filters pubtype-select" data-filter-group="pubtype">
          <option value="*">All</option>
          
          <option value=".pubtype-2">
            Journal article
          </option>
          
        </select>

        <select class="pub-filters" data-filter-group="year">
          <option value="*">All</option>
          
          
          
          <option value=".year-2020">
            2020
          </option>
          
          <option value=".year-2019">
            2019
          </option>
          
          <option value=".year-2018">
            2018
          </option>
          
          <option value=".year-2017">
            2017
          </option>
          
          <option value=".year-2016">
            2016
          </option>
          
          <option value=".year-2014">
            2014
          </option>
          
          <option value=".year-2013">
            2013
          </option>
          
          <option value=".year-2012">
            2012
          </option>
          
          <option value=".year-2011">
            2011
          </option>
          
          
        </select>
      </p>

      <div id="container-publications">
        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2020">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2020-05-29-scclusteval/">
      
      
        <img src="/img/headers/scclusteval_flow.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2020-05-29-scclusteval/" itemprop="url">Evaluating single-cell cluster stability using the Jaccard similarity index</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Motivation: One major goal of single-cell RNA sequencing (scRNAseq) experiments is to identify novel cell types. With increasingly large scRNAseq datasets, unsupervised clustering methods can now produce detailed catalogues of transcriptionally distinct groups of cells in a sample. However, the interpretation of these clusters is challenging for both technical and biological reasons. Popular clustering algorithms are sensitive to parameter choices, and can produce different clustering solutions with even small changes in the number of principal components used, the k nearest neighbor, and the resolution parameters, among others. Results: Here, we present a set of tools to evaluate cluster stability by subsampling, which can guide parameter choice and aid in biological interpretation. The R package scclusteval and the accompanying Snakemake workflow implement all steps of the pipeline: subsampling the cells, repeating the clustering with Seurat, and estimation of cluster stability using the Jaccard similarity index. The Snakemake workflow takes advantage of high-performance computing clusters and dispatches jobs in parallel to available CPUs to speed up the analysis. The scclusteval package provides functions to facilitate the analysis of the output, including a series of rich visualizations. Availability: R package scclusteval: <a href="https://github.com/crazyhottommy/scclusteval" target="_blank">https://github.com/crazyhottommy/scclusteval</a> Snakemake workflow: <a href="https://github.com/crazyhottommy/pyflow_seuratv3_parameter" target="_blank">https://github.com/crazyhottommy/pyflow_seuratv3_parameter</a>.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Biorxiv</em>,
    
    2020
  </div>

  <div class="pub-links">
    



<a class="btn btn-primary btn-outline btn-xs" href="https://www.biorxiv.org/content/10.1101/2020.05.26.116640v1" target="_blank" rel="noopener">
  Preprint
</a>
















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2020">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2020-04-03-kmt2d-lung-cancer/">
      
      
        <img src="/img/headers/KMT2D.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2020-04-03-kmt2d-lung-cancer/" itemprop="url">KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Epigenetic modifiers frequently harbor loss-of-function mutations in lung cancer, but their tumor-suppressive roles are poorly characterized. Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer. Here, we show that lung-specific loss of Kmt2d promotes lung tumorigenesis in mice and upregulates pro-tumorigenic programs, including glycolysis. Pharmacological inhibition of glycolysis preferentially impedes tumorigenicity of human lung cancer cells bearing KMT2D-inactivating mutations. Mechanistically,Kmt2d loss widely impairs epigenomic signals for super-enhancers/enhancers, including the super-enhancer for the circadian rhythm repressor Per2. Loss of Kmt2d decreases expression of PER2, which regulates multiple glycolytic genes. These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycolytic inhibitors.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Hunain Alam*, <strong>Ming Tang</strong>*, Mayinuer Maitituoheti et.al, * Co-first author
    
  </div>

  <div class="pub-publication">
    
    In <em>Cancer Cell</em>,
    
    2020
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/KMT2D_lung_cancer.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2020">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2020-03-20-kallisto-scatac/">
      
      
        <img src="/img/headers/kallisto.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2020-03-20-kallisto-scatac/" itemprop="url">Fast analysis of scATAC-seq data using a predefined set of genomic regions</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Background: Analysis of scATAC-seq data has been recently scaled to thousands of cells. While processing of other types of single cell data was boosted by the implementation of alignment-free techniques, pipelines available to process scATAC-seq data still require large computational resources. We propose here an approach based on pseudoalignment, which reduces the execution times and hardware needs at little cost for precision. Methods: Public data for 10k PBMC were downloaded from 10x Genomics web site. Reads were aligned to various references derived from DNase I Hypersensitive Sites (DHS) using kallisto and quantified with bustools. We compared our results with the ones publicly available derived by cellranger-atac. Results: We found that kallisto does not introduce biases in quantification of known peaks and cells groups are identified in a consistent way. We also found that cell identification is robust when analysis is performed using DHS-derived reference in place of de novo identification of ATAC peaks. Lastly, we found that our approach is suitable for reliable quantification of gene activity based on scATAC-seq signal, thus allows for efficient labelling of cell groups based on marker genes.Conclusions: Analysis of scATAC-seq data by means of kallisto produces results in line with standard pipelines while being considerably faster; using a set of known DHS sites as reference does not affect the ability to characterize the cell populations
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Valentina Giansanti, <strong>Ming Tang</strong>, Davide Cittaro
    
  </div>

  <div class="pub-publication">
    
    In <em>F1000 Research</em>,
    
    2020
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/kallisto_scATAC.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2020">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2020-02-19-lats-ctcf/">
      
      
        <img src="/img/headers/LATS.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2020-02-19-lats-ctcf/" itemprop="url">LATS kinase–mediated CTCF phosphorylation and selective loss of genomic binding</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Chromatin topological organization is instrumental in gene transcription. Gene-enhancer interactions are accommodated in the same CTCF-mediated insulated neighborhoods. However, it remains poorly understood whether and how the 3D genome architecture is dynamically restructured by external signals. Here, we report that LATS kinases phosphorylated CTCF in the zinc finger (ZF) linkers and disabled its DNA-binding activity. Cellular stress induced LATS nuclear translocation and CTCF ZF linker phosphorylation, and altered the landscape of CTCF genomic binding partly by dissociating it selectively from a small subset of its genomic binding sites. These sites were highly enriched for the boundaries of chromatin domains containing LATS signaling target genes. The stress-induced CTCF phosphorylation and locus-specific dissociation from DNA were LATS-dependent. Loss of CTCF binding disrupted local chromatin domains and down-regulated genes located within them. The study suggests that external signals may rapidly modulate the 3D genome by affecting CTCF genomic binding through ZF linker phosphorylation.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Huacheng Luo, Qin Yu, Yang Liu, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Science Advances</em>,
    
    2020
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/LATS_CTCF.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2019">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2019-03-20-irf2/">
      
      
        <img src="/img/headers/IRF2_KRAS.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2019-03-20-irf2/" itemprop="url">KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    The biological functions and mechanisms of oncogenic KRASG12D(KRAS) in resistance to immune check-point blockade (ICB) therapy are not fully understood. We demonstrate that KRAS* represses the expressionof interferon regulatory factor 2 (IRF2), which in turn directly represses CXCL3 expression. KRAS*-mediatedrepression of IRF2 results in high expression of CXCL3, which binds to CXCR2 on myeloid-derived suppres-sor cells and promotes their migration to the tumor microenvironment. Anti-PD-1 resistance of KRAS-ex-pressing tumors can be overcome by enforced IRF2 expression or by inhibition of CXCR2. Colorectal cancer(CRC) showing higher IRF2 expression exhibited increased responsiveness to anti-PD-1 therapy. The KRAS-IRF2-CXCL3-CXCR2 axis provides a framework for patient selection and combination therapies to enhancethe effectiveness of ICB therapy in CRC
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Wenting Liao, Michael J. Overman, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cancer Cell</em>,
    
    2019
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/KRAS_IRF2.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2018">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2018-10-05-hdac-inhibitor/">
      
      
        <img src="/img/headers/HDAC.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2018-10-05-hdac-inhibitor/" itemprop="url">Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Chemoresistance may be due to the survival of leukemia stem cells (LSCs) that are quiescent and not responsive to chemotherapy or lie on the intrinsic or acquired resistance of the specific pool of AML cells. Here, we found, among well-established LSC markers, only CD123 and CD47 are correlated with AML cell chemosensitivities across cell lines and patient samples. Further study reveals that percentages of CD123+CD47+ cells significantly increased in chemoresistant lines compared to parental cell lines. However, stemness signature genes are not significantly increased in resistant cells. Instead, gene changes are enriched in cell cycle and cell survival pathways. This suggests CD123 may serve as a biomarker for chemoresistance, but not stemness of AML cells. We further investigated the role of epigenetic factors in regulating the survival of chemoresistant leukemia cells. Epigenetic drugs, especially histone deacetylase inhibitors (HDACis), effectively induced apoptosis of chemoresistant cells. Furthermore, HDACi Romidepsin largely reversed gene expression profile of resistant cells and efficiently targeted and removed chemoresistant leukemia blasts in xenograft AML mouse model. More interestingly, Romidepsin preferentially targets CD123+ cells, while chemotherapy drug Ara-C mainly targeted fast-growing, CD123− cells. Therefore, Romidepsin alone or in combination with Ara-C may be a potential treatment strategy for chemoresistant patients.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Bowen Yan, Qinwei Chen, Koji Shimada, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Leukemia</em>,
    
    2018
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/HDAC-inhibitor.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2018">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2018-09-18-egfr-nsclc/">
      
      
        <img src="/img/headers/EGFR_NSLC.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2018-09-18-egfr-nsclc/" itemprop="url">Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    PURPOSE:Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described.EXPERIMENTAL DESIGN:Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients.RESULTS:In the 118 patients treated with osimertinib, 42 had molecular profiling at progression. T790M was preserved in 21 (50%) patients and lost in 21 (50%). EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases. MET amplification was the second most common alteration (14%). Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET. Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers. Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01). In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months. Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02). CONCLUSIONS:Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Xiuning Le, Sonam Puri, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Clinical Cancer Research</em>,
    
    2018
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/EGFR_NSLC.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2018">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2018-08-21-ptefb/">
      
      
        <img src="/img/headers/p-TEFb.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2018-08-21-ptefb/" itemprop="url">Positive Regulation of Transcription by Human ZMYND8 through Its Association with P-TEFb Complex</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Although human ZMYND8 has been implicated as a transcriptional co-repressor of multiple targets, global association of ZMYND8 with active genes and enhancer regions predicts otherwise. Here, we report an additional function of ZMYND8 in transcriptional activation through its association with the P-TEFb complex. Biochemical reconstitution analyses show that human ZMYND8, through direct association with CylcinT1, forms a minimal ZMYND8-P-TEFb complex. The importance of ZMYND8 in target gene activation, through P-TEFb complex recruitment, is demonstrated on chromosomally integrated reporter gene as well as native target genes in vivo. Physiologically, we further show that the ZMYND8-P-TEFb complex-mediated transcriptional activation is required for all-trans retinoic acid (ATRA)-mediated differentiation of neuronal precursor cells. Finally, to detail the dual activator and repressor nature, mechanistically we show that, through its putative coiled-coil domain, ZMYND8 forms a homodimer that preferentially associates with the activator P-TEFb complex, whereas the monomer associates with the CHD4 subunit of repressor NuRD complex.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Koushik Ghosh, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cell Reports</em>,
    
    2018
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/p-TEFb.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2018">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2018-07-12-tandem-duplicate/">
      
      
        <img src="/img/headers/tandem-duplicates.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2018-07-12-tandem-duplicate/" itemprop="url">The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    The tandem duplicator phenotype (TDP) is a genome-wide instability configuration primarily observed in breast, ovarian, and endometrial carcinomas. Here, we stratify TDP tumors by classifying their tandem duplications (TDs) into three span intervals, with modal values of 11 kb, 231 kb, and 1.7 Mb, respectively. TDPs with ∼11 kb TDs feature loss of TP53 and BRCA1. TDPs with ∼231 kb and ∼1.7 Mb TDs associate with CCNE1 pathway activation and CDK12 disruptions, respectively. We demonstrate that p53 and BRCA1 conjoint abrogation drives TDP induction by generating short-span TDP mammary tumors in genetically modified mice lacking them. Lastly, we show how TDs in TDP tumors disrupt heterogeneous combinations of tumor suppressors and chromatin topologically associating domains while duplicating oncogenes and super-enhancers.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Francesca Menghi, Floris P. Barthel, Vinod Yadav, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cancer Cell</em>,
    
    2018
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/tandem_DUP.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2018">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2018-04-05-jove-chipseq/">
      
      
        <img src="/img/headers/chromHMM.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2018-04-05-jove-chipseq/" itemprop="url">An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Histone modifications constitute a major component of the epigenome and play important regulatory roles in determining the transcriptional status of associated loci. In addition, the presence of specific modifications has been used to determine the position and identity non-coding functional elements such as enhancers. In recent years, chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) has become a powerful tool in determining the genome-wide profiles of individual histone modifications. However, it has become increasingly clear that the combinatorial patterns of chromatin modifications, referred to as Chromatin States, determine the identity and nature of the associated genomic locus. Therefore, workflows consisting of robust high-throughput (HT) methodologies for profiling a number of histone modification marks, as well as computational analyses pipelines capable of handling myriads of ChIP-Seq profiling datasets, are needed for comprehensive determination of epigenomic states in large number of samples. The HT-ChIP-Seq workflow presented here consists of two modules: 1) an experimental protocol for profiling several histone modifications from small amounts of tumor samples and cell lines in a 96-well format; and 2) a computational data analysis pipeline that combines existing tools to compute both individual mark occupancy and combinatorial chromatin state patterns. Together, these two modules facilitate easy processing of hundreds of ChIP-Seq samples in a fast and efficient manner. The workflow presented here is used to derive chromatin state patterns from 6 histone mark profiles in melanoma tumors and cell lines. Overall, we present a comprehensive ChIP-seq workflow that can be applied to dozens of human tumor samples and cancer cell lines to determine epigenomic aberrations in various malignancies.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Christopher Terranova, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>JOVE</em>,
    
    2018
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/jove-ChIPseq.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2018">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2018-01-04-tumor-fusions/">
      
      
        <img src="/img/headers/fusion.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2018-01-04-tumor-fusions/" itemprop="url">TumorFusions: an integrative resource for cancer-associated transcript fusions</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Gene fusion represents a class of molecular aberrations in cancer and has been exploited for therapeutic purposes. In this paper we describe Tumor-Fusions, a data portal that catalogues 20731 gene fusions detected in 9966 well characterized cancer samples and 648 normal specimens from The Cancer Genome Atlas (TCGA). The portal spans 33 cancer types in TCGA. Fusion transcripts were identified via a uniform pipeline, including filtering against a list of 3838 transcript fusions detected in a panel of 648 non-neoplastic samples. Fusions were mapped to somatic DNA rearrangements identified using whole genome sequencing data from 561 cancer samples as a means of validation. We observed that 65% of transcript fusions were associated with a chromosomal alteration, which is annotated in the portal. Other features of the portal include links to SNP array-based copy number levels and mutational patterns, exon and transcript level expressions of the partner genes, and a network-based centrality score for prioritizing functional fusions. Our portal aims to be a broadly applicable and user friendly resource for cancer gene annotation and is publicly available at <a href="http://www.tumorfusions.org" target="_blank">http://www.tumorfusions.org</a>
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Xin Hu, Qianghu Wang, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Nucleic Acids Research</em>,
    
    2018
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/TumorFusions.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2017">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2016-06-21-mof-emt/">
      
      
        <img src="/img/headers/EMT-MOF.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2016-06-21-mof-emt/" itemprop="url">MOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    The histone demethylase LSD1 facilitates epithelialto-mesenchymal transition (EMT) and tumor progression by repressing epithelial marker expression. However, little is known about how its function may be modulated. Here, we report that LSD1 is acetylated in epithelial but not mesenchymal cells. Acetylation of LSD1 reduces its association with nucleosomes, thus increasing histone H3K4 methylation at its target genes and activating transcription. The MOF acetyltransferase interacts with LSD1 and is responsible for its acetylation. MOF is preferentially expressed in epithelial cells and is downregulated by EMT-inducing signals. Expression of exogenous MOF impedes LSD1 binding to epithelial gene promoters and histone demethylation, thereby suppressing EMT and tumor invasion. Conversely, MOFdepletion enhances EMT and tumor metastasis. In human cancer, high MOF expression correlates with epithelial markers and a favorable prognosis. These findings provide insight into the regulation of LSD1 and EMT and identify MOF as a critical suppressor of EMT and tumor progression.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Huacheng Luo, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cell Reports</em>,
    
    2017
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/MOF_EMT.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2017">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2017-08-14-uveal-melanoma/">
      
      
        <img src="/img/headers/Uveal.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2017-08-14-uveal-melanoma/" itemprop="url">Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with betterprognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM. Poor-prognosis M3-UMdivide into subsets with divergent genomic aberrations, transcriptional features, and clinical outcomes. We report change-of-function SRSF2 mutations. Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    A. Gordon Robertson, TCGA network, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cancer Cell</em>,
    
    2017
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/Uveal.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2017">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2017-06-28-tfii-i-e2f/">
      
      
        <img src="/img/headers/TFII-I-2.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2017-06-28-tfii-i-e2f/" itemprop="url">Functional interrelationship between TFII-I and E2F transcription factors at specific cell cycle gene loci</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Transcription factor TFII-I is a multifunctional protein implicated in the regulation of cell cycle and stress-response genes. Previous studies have shownthat a subset of TFIII associated genomic sites containedDNA-bindingmotifs for E2F family transcription factors. We analyzed the co-association of TFII-I and E2Fs in more detail using bioinformatics, chromatin immunoprecipitation, and co-immunoprecipitation experiments. The data showthat TFII-I interacts with E2F transcription factors. Furthermore, TFII-I, E2F4, and E2F6 interact with DNA-regulatory elements of several genes implicated in the regulation of the cell cycle, including DNMT1, HDAC1, CDKN1C, and CDC27. Inhibition of TFII-I expression led to a decrease in gene expression and in the association of E2F4 andE2F6 with these gene loci in humanerythroleukemia K562 cells. Finally, TFII-I deficiency reduced the proliferation of K562 cells and increased the sensitivity toward doxorubicin toxicity. The results uncover novel interactions between TFII-I and E2Fs and suggest that TFII-I mediates E2F function at specific cell cycle genes.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Yong Shen, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>JCB</em>,
    
    2017
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/TFII-I-E2F.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2017">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2017-03-01-telomere-pan-cancer/">
      
      
        <img src="/img/headers/telomere-pan.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2017-03-01-telomere-pan-cancer/" itemprop="url">Systematic analysis of telomere length and somatic alterations in 31 cancer types</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Cancer cells survive cellular crisis through telomere maintenance mechanisms. We report telomere lengths in 18,430 samples, including tumors and non-neoplastic samples, across 31 cancer types. Telomeres were shorter in tumors than in normal tissues and longer in sarcomas and gliomas than in other cancers. Among 6,835 cancers, 73% expressed telomerase reverse transcriptase (TERT), which was associated with TERT point mutations, rearrangements, DNA amplifications and transcript fusions and predictive of telomerase activity. TERT promoter methylation provided an additional deregulatory TERT expression mechanism. Five percent of cases, characterized by undetectable TERT expression and alterations in ATRX or DAXX, demonstrated elongated telomeres and increased telomeric repeat–containing RNA (TERRA). The remaining 22% of tumors neither expressed TERT nor harbored alterations in ATRX or DAXX. In this group, telomere length positively correlated with TP53 and RB1 mutations. Our analysis integrates TERT abnormalities, telomerase activity and genomic alterations with telomere length in cancer.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Floris P Barthel, Wei Wei, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Nature Genetics</em>,
    
    2017
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/telemere.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2017">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2017-02-23-pten-synthetic/">
      
      
        <img src="/img/headers/CHD1-PTEN.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2017-02-23-pten-synthetic/" itemprop="url">Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Synthetic lethality and collateral lethality are two well-validated conceptual strategies for identifying therapeutic targets in cancers with tumour-suppressor gene deletions1–3. Here, we explore an approach to identify potential synthetic-lethal interactions by screening mutually exclusive deletion patterns in cancer genomes. We sought to identify ‘synthetic-essential’ genes: those that are occasionally deleted in some cancers but are almost always retained in the context of a specific tumour-suppressor deficiency. We also posited that such synthetic-essential genes would be therapeutic targets in cancers that harbour specific tumour-suppressor deficiencies. In addition to known synthetic-lethal interactions, this approach uncovered the chromatin helicase DNA-binding factor CHD1 as a putative synthetic-essential gene in PTEN-deficient cancers. In PTEN-deficient prostate and breast cancers, CHD1 depletion profoundly and specifically suppressed cell proliferation, cell survival and tumorigenic potential. Mechanistically, functional PTEN stimulates the GSK3β-mediated phosphorylation of CHD1 degron domains, which promotes CHD1 degradation via the β-TrCP-mediated ubiquitination–proteasome pathway. Conversely, PTEN deficiency results in stabilization of CHD1, which in turn engages the trimethyl lysine-4 histone H3 modification to activate transcription of the pro-tumorigenic TNF–NF-κB gene network. This study identifies a novel PTEN pathway in cancer and provides a framework for the discovery of ‘trackable’ targets in cancers that harbour specific tumour-suppressor deficiencies.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Di Zhao, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Nature</em>,
    
    2017
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/CHD1_PTEN.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2017">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2017-02-15-ifn-signaling-tumor-pd1-resistance/">
      
      
        <img src="/img/headers/anti-PD1.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2017-02-15-ifn-signaling-tumor-pd1-resistance/" itemprop="url">Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistance by in vivo passaging of Kras-mutated, p53-deficient murine lung cancer cells (p53R172HDg/þK-rasLA1/þ) in a syngeneic host exposed to repetitive dosing with anti-mouse PD-1 antibodies. PD-L1 (CD274) expression did not differ between the resistant and parental tumor cells. However, the expression of important molecules in the antigen presentation pathway, including MHC class I and II, as well as b2-microglobulin, were significantly downregulated in the anti-PD-1–resistant tumors compared with parental tumors. Resistant tumors also contained fewer CD8þ (CD8a) and CD4þ tumor-infiltrating lymphocytes and reduced production of IFNg. Localized radiotherapy induced IFNb production, thereby elevating MHC class I expression on both parental and resistant tumor cells and restoring the responsiveness of resistant tumors to anti-PD-1 therapy. Conversely, blockade of type I IFN signaling abolished the effect of radiosensitization in this setting. Collectively, these results identify a mechanism of PD-1 resistance and demonstrate that adjuvant radiotherapy can overcome resistance. These findings have immediate clinical implications for extending the efficacy of anti-PD-1 immune checkpoint therapy in patients.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Xiaohong Wang, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cancer Research</em>,
    
    2017
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/IFN_PD1.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2016">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2016-11-01-emt-pericyte/">
      
      
        <img src="/img/headers/EMT-pericyte.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2016-11-01-emt-pericyte/" itemprop="url">Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Carcinoma cells can acquire increased motility and invasiveness through epithelial-to-mesenchymal transition (EMT). However, the significance of EMT in cancer metastasis has been controversial, and the exact fates and functions of EMT cancer cells in vivo remain inadequately understood. Here, we tracked epithelial cancer cells that underwent inducible or spontaneous EMT in various tumor transplantation models. Unlike epithelial cells, the majority of EMT cancer cells were specifically located in the perivascular space and closely associated with blood vessels. EMT markedly activated multiple pericyte markers in carcinoma cells, in particular PDGFR-β and N-cadherin, which enabled EMT cells to be chemoattracted towards and physically interact with endothelium. In tumor xenografts generated from carcinoma cells that were prone to spontaneous EMT, a substantial fraction of the pericytes associated with tumor vasculature were derived from EMT cancer cells. Depletion of such EMT cells in transplanted tumors diminished pericyte coverage, impaired vascular integrity, and attenuated tumor growth. These findings suggest that EMT confers key pericyte attributes on cancer cells. The resulting EMT cells phenotypically and functionally resemble pericytes and are indispensable for vascular stabilization and sustained tumor growth. This study thus proposes a previously unrecognized role for EMT in cancer.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Anitha K. Shenoy, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>JCI</em>,
    
    2016
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/EMT_pericyte.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2016">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2016-05-31-take-rhabdoid/">
      
      
        <img src="/img/headers/trends-in-cancer.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2016-05-31-take-rhabdoid/" itemprop="url">A Molecular Take on Malignant Rhabdoid Tumors</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular intertumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic, and epigenomic profiling. Distinct molecular subgroups were identified and new therapeutic targets were revealed.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    <strong>Ming Tang</strong>, and Roel Verhaak
    
  </div>

  <div class="pub-publication">
    
    In <em>Trends in Cancer</em>,
    
    2016
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/Rhabdoid.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2014">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2014-09-01-trim29-twist1-breast-cancer/">
      
      
        <img src="/img/headers/TWIST-TRIM29.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2014-09-01-trim29-twist1-breast-cancer/" itemprop="url">TRIM29 Suppresses TWIST1 and Invasive Breast Cancer Behavior</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    TRIM29 (ATDC) exhibits a contextual function in cancer, but seems to exert a tumor-suppressor role in breast cancer. Here, we show that TRIM29 is often silenced in primary breast tumors and cultured tumor cells as a result of aberrant gene hypermethylation. RNAi-mediated silencing of TRIM29 in breast tumor cells increased their motility, invasiveness, and proliferation in a manner associated with increased expression of mesenchymal markers (N-cadherin and vimentin), decreased expression of epithelial markers (E-cadherin and EpCAM), and increased expression and activity of the oncogenic transcription factor TWIST1, an important driver of the epithelial–mesenchymal transition (EMT). Functional investigations revealed an inverse relationship in the expression of TRIM29 and TWIST1, suggesting the existence of a negative regulatory feedback loop. In support of this relationship, we found that TWIST1 inhibited TRIM29 promoter activity through direct binding to a region containing a cluster of consensus E-box elements, arguing that TWIST1 transcriptionally represses TRIM29 expression. Analysis of a public breast cancer gene-expression database indicated that reduced TRIM29 expression was associated with reduced relapse-free survival, increased tumor size, grade, and metastatic characteristics. Taken together, our results suggest that TRIM29 acts as a tumor suppressor in breast cancer through its ability to inhibit TWIST1 and suppress EMT.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Lingbao Ai, Wan-Ju Kim, Merve Alpay, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Cancer Research</em>,
    
    2014
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/TWIST1-TRIM29.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2014">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2014-05-29-tfii-i-genomics/">
      
      
        <img src="/img/headers/TFII-I.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2014-05-29-tfii-i-genomics/" itemprop="url">Genomic and proteomic analysis of transcription factor TFII-I reveals insight into the response to cellular stress</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    The ubiquitously expressed transcription factor TFIII exerts both positive and negative effects on transcription. Using biotinylation tagging technology and high-throughput sequencing, we determined sites of chromatin interactions for TFII-I in the human erythroleukemia cell line K562. This analysis revealed that TFII-I binds upstream of the transcription start site of expressed genes, both upstream and downstream of the transcription start site of repressed genes, and downstream of RNA polymerase II peaks at the ATF3 and other stress responsive genes. At the ATF3 gene, TFII-I binds immediately downstream of a Pol II peak located 5 kb upstream of exon 1. Induction of ATF3 expression increases transcription throughout the ATF3 gene locus which requires TFIII and correlates with increased association of Pol II and Elongin A. Pull-down assays demonstrated that TFII-I interacts with Elongin A. Partial depletion of TFII-I expression caused a reduction in the association of Elongin A with and transcription of the DNMT1 and EFR3A genes without a decrease in Pol II recruitment. The data reveal different interaction patterns of TFII-I at active, repressed, or inducible genes, identify novel TFII-I interacting proteins, implicate TFII-I in the regulation of transcription elongation and provide insight into the role of TFII-I during the response to cellular stress.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    Alex Xiucheng Fan, &hellip;, <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>Nucleic Acids Research</em>,
    
    2014
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/TFII-I.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2013">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2013-09-20-sfmbt-snail-emt-cancer/">
      
      
        <img src="/img/headers/SFMBT-LSD1.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2013-09-20-sfmbt-snail-emt-cancer/" itemprop="url">The malignant brain tumor (MBT) domain protein SFMBT1 is an integral histone reader subunit of the LSD1 demethylase complex for chromatin association and epithelial-to-mesenchymal transition</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Chromatin readers decipher the functional readouts of histone modifications by recruiting specific effector complexes for subsequent epigenetic reprogramming. The LSD1 (also known as KDM1A) histone demethylase complex modifies chromatin and represses transcription in part by catalyzing demethylation of dimethylated histone H3 lysine 4 (H3K4me2), a mark for active transcription. However, none of its currently known subunits recognizes methylated histones. The Snai1 family transcription factors are central drivers of epithelial-to-mesenchymal transition (EMT) by which epithelial cells acquire enhanced invasiveness. Snai1-mediated transcriptional repression of epithelial genes depends on its recruitment of the LSD1 complex and ensuing demethylation of H3K4me2 at its target genes. Through biochemical purification, we identified the MBT domain-containing protein SFMBT1 as a novel component of the LSD1 complex associated with Snai1. Unlike other mammalian MBT domain proteins characterized to date that selectively recognize mono- and dimethylated lysines, SFMBT1 binds diand trimethyl H3K4, both of which are enriched at active promoters. We show that SFMBT1 is essential for Snai1-dependent recruitment of LSD1 to chromatin, demethylation of H3K4me2, transcriptional repression of epithelial markers, and induction of EMT by TGFb. Carcinogenic metal nickel is a widespread environmental and occupational pollutant. Nickel alters gene expression and induces EMT. We demonstrate the nickel-initiated effects are dependent on LSD1-SFMBT1-mediated chromatin modification. Furthermore, in human cancer, expression of SFMBT1 is associated with mesenchymal markers and unfavorable prognosis. These results highlight a critical role of SFMBT1 in epigenetic regulation, EMT, and cancer.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>JBC</em>,
    
    2013
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/SFMBT1-LSD1.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2012">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2012-03-01-ctcf-angiogenesis/">
      
      
        <img src="/img/headers/CTCF_VEGF.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2012-03-01-ctcf-angiogenesis/" itemprop="url">CTCF-dependent chromatin insulator as a built-in attenuator of angiogenesis</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    VEGF is a pivotal pro-angiogenic growth factor and its dosage decisively impacts vascularization. We recently identified a CTCF-dependent chromatin insulator that critically restrains the transcriptional induction of VEGF and angiogenesis. We postulate that CTCF may exert enhancer blocking by mediating chromatin looping and/or RNA polymerase pausing at the VEGF locus.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    <strong>Ming Tang</strong>, Jianrong Lu
    
  </div>

  <div class="pub-publication">
    
    In <em>Transcription</em>,
    
    2012
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/CTCF-angiogenesis.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        

        
          
        

        <div class="grid-sizer col-md-12 isotope-item pubtype-2 year-2011">
          
            <div class="pub-list-item card-simple" itemscope itemtype="http://schema.org/CreativeWork">

  
    
  
  
  <div>
    <a href="/publication/2011-09-13-ctcf-vegf-enhancer-blocking/">
      
      
        <img src="/img/headers/CTCF-retina-angiogenesis.png" class="article-banner" itemprop="image">
      
    </a>
  </div>
  

  <h3 class="article-title" itemprop="name">
    <a href="/publication/2011-09-13-ctcf-vegf-enhancer-blocking/" itemprop="url">Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation</a>
  </h3>

  <div class="pub-abstract" itemprop="text">
    
    Angiogenesis is meticulously controlled by a fine balance between positive and negative regulatory activities. Vascular endothelial growth factor (VEGF) is a predominant angiogenic factor and its dosage is precisely regulated during normal vascular formation. In cancer, VEGF is commonly overproduced, resulting in abnormal neovascularization. VEGF is induced in response to various stimuli including hypoxia; however, very little is known about the mechanisms that confine its induction to ensure proper angiogenesis. Chromatin insulation is a key transcription mechanism that prevents promiscuous gene activation by interfering with the action of enhancers. Here we show that the chromatin insulator-binding factor CTCF binds to the proximal promoter of VEGF. Consistent with the enhancer-blocking mode of chromatin insulators, CTCF has little effect on basal expression of VEGF but specifically affects its activation by enhancers. CTCF knockdown cells are sensitized for induction of VEGF and exhibit elevated proangiogenic potential. Cancer-derived CTCF missense mutants are mostly defective in blocking enhancers at the VEGF locus. Moreover, during mouse retinal development, depletion of CTCF causes excess angiogenesis. Therefore, CTCF-mediated chromatin insulation acts as a crucial safeguard against hyperactivation of angiogenesis.
    
  </div>

  <div class="pub-authors" itemprop="author">
    
    <strong>Ming Tang</strong> et.al
    
  </div>

  <div class="pub-publication">
    
    In <em>PNAS</em>,
    
    2011
  </div>

  <div class="pub-links">
    




<a class="btn btn-primary btn-outline btn-xs" href="/files/papers/CTCF-insulator.pdf" target="_blank" rel="noopener">
  PDF
</a>















  </div>

</div>

          
        </div>

        
      </div>

    </div>
  </div>
</div>
<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      &copy; 2018 Ming Tang &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    
    <script id="dsq-count-scr" src="//divingintogeneticsandgenomics.disqus.com/count.js" async></script>
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

